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Abstract
Background: T-helper polarization of naı¨ve T cells is determined by a complex mechanism that involves many factors,
eventually leading to activation of Th1, Th2, or Th17 responses or alternatively the generation of regulatory T cells. Placental
Protein 14 (PP14) is a 28 kDa glycoprotein highly secreted in early pregnancy that is able to desensitize T cell receptor (TCR)
signaling and modulate T cell activation.
Methodology/Principal Findings: Prolonged antigen-specific stimulation of T cells in the presence of PP14 resulted in an
impaired secretion of IFN-c, IL-5 and IL-17 upon restimulation, although the cells proliferated and expressed activation
markers. Furthermore, the generation of regulatory CD4+CD25highFoxp3+ T cells was induced in the presence of PP14, in
both antigen-specific as well as polyclonal stimulation. In accordance with previous reports, we found that the induction of
FoxP3 expression by PP14 is accompanied by down regulation of the PI3K-mTOR signaling pathway.
Conclusions/Significance: These data suggest that PP14 arrests T cells in a unique activated state that is not accompanied
with the acquisition of effector function, together with promoting the generation of regulatory T cells. Taken together, our
results may elucidate the role of PP14 in supporting immune tolerance in pregnancy by reducing T cell effector functions
along with augmenting Treg differentiation.
Citation: Ochanuna Z, Geiger-Maor A, Dembinsky-Vaknin A, Karussis D, Tykocinski ML, et al. (2010) Inhibition of Effector Function but Not T Cell Activation and
Increase in FoxP3 Expression in T Cells Differentiated in the Presence of PP14. PLoS ONE 5(9): e12868. doi:10.1371/journal.pone.0012868
Editor: Derya Unutmaz, New York University, United States of America
Received April 26, 2010; Accepted July 24, 2010; Published September 23, 2010
Copyright:  2010 Ochanuna et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Horowitz foundation and the National Multiple Sclerosis Society. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rjacob@cc.huji.ac.il
Introduction
PP14 is a glycoprotein that belongs to the lipocalin superfamily,
of which most members are extracellular proteins that function in
transporting small hydrophobic ligands [1]. PP14, also known as
glycodelin, appears in various glycoforms: 1) follicular PP14
(Glycodelin F) that is expressed in the follicular fluid and inhibits
sperm-oocyte binding; 2) seminal PP14 (Glycodelin S) that is
expressed in the seminal fluid and maintains the uncapacitated
state of the sperm; and 3) the amniotic glycoform (Glycodelin A)
[2]. Amniotic PP14 is mainly synthesized in secretory endometrial
glands and by gestational decidua where it is regulated by
progesterone and it is the major secretory protein of human
endometrial epithelial cells during the luteal phase and early
pregnancy [3]. Maternal serum levels of PP14 increase during the
second half of the luteal phase and peak around the onset of
menses. PP14 concentrations rise rapidly in early pregnancy, with
the highest concentrations found in the decidua between the 6th
and 12th week of gestation. A correlation between low serum
levels of PP14 and susceptible abortion has been recognized. This
and other evidences suggest that high levels of PP14 may have an
important role for establishment, maintenance, and progression of
pregnancy and for early survival of the developing fetoplacental
unit [4].
In addition to contraceptive and pro-angiogenic activities of
amniotic PP14 [5,6] several reports in the late 1980’s pointed to
PP14’s immunoregulatory potential, with its capacities to inhibit:
1) T cell proliferation in allogeneic two-way mixed lymphocyte
reactions; 2) mitogenic responsiveness of lymphocytes to the lectin
PHA; 3) pro-inflammatory cytokine (IL-1 and IL-2) production by
immune cells and 4) natural killer (NK) cell cytotoxicity [4,7,8].
More recent studies have demonstrated that PP14 can induce
apoptosis in T cells [9,10,11].
In the present and previous studies we have used recombinant
PP14?Fcc1 produced in the human kidney 293 cells. It has been
previously shown that recombinant PP14 produced in these cells
has the same type of carbohydrate structures as that of the
amniotic PP14 [12].
Key findings from our group pertaining to PP14’s mode of
action, suggest a novel paradigm for immunoinhibition wherein
PP14 finely tunes, rather than inactivates, T cell responses. These
studies demonstrated that PP14 mediates its anti-inflammatory
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activity by elevating T cell activation thresholds, thereby rendering
T cells less sensitive to a given level of T cell receptor (TCR)
stimulation [13]. Molecularly, PP14’s inhibition depends on the
presence of the surface tyrosine phosphatase CD45 [14] as well as
upon its access to triggered TCR within antigen-presenting cell
(APC):T cell contact sites, where it decreases the stability of TCR-
induced phosphoproteins, hence explaining the TCR desensitiza-
tion effect [13]. PP14 binds to T cell surfaces in a carbohydrate-
dependent fashion – preferentially binding to sialylated N-
acetyllactosamine. This seminal insight creates an intriguing link
between PP14 and other immunoregulatory lectins (namely,
galectin-1 and CD22) whose activity depends upon CD45 [15].
This carbohydrate binding profile correlates well with PP14’s
preferential co-capping of CD45RA isoform (presumably due to
high degree of sialylation) and preferential inhibition of CD45RA+
(naı¨ve) T cells [16].
This mechanistic insight into PP14’s threshold modulation
activity at the molecular level provided a useful framework for
further exploring PP14’s impact on T cell responses. Testing
PP14’s impact on early responses during polyclonal activation of
bulk T cells, we have previously demonstrated that PP14
preferentially inhibits Th1 responses as compared with Th2
[17], in accordance with their respective known TCR signaling
thresholds [18] and as expected for a threshold-centered
mechanism [13].
Armed with these findings for bulk polyclonal activated T cells,
in the present study we moved to longer-term assays of antigen-
specific T cells, in order to further elucidate the immunological
effects of PP14, particularly on Th subset differentiation.
Results
PP14?Fcc1-treated MBP-specific T cells fail to develop
into T effectors
Previous experiments in our lab so far dealt with PP14’s impact
on early responses during polyclonal activation of bulk T cells.
Under these conditions we have demonstrated that PP14
preferentially inhibits Th1 responses as compared with Th2
[17]. In order to determine the consequence of PP14 treatment on
Ag-specific T cell polarization over time and the way it may shape
T helper response, we first used PBMC from healthy donors that
were stimulated with myelin basic protein (MBP). MBP-reactive T
cells from healthy donors are presumed not to be encountering
their cognate CNS auto-antigens, and are most appropriate for
studies of Th polarization [19]. MBP-specific T cells were
generated in the presence or absence of PP14?Fcc1, as described
in Materials and Methods, and then restimulated with MBP, this time
without PP14?Fcc1 in order to characterize the developmental fate
of the cells. Previous studies have established transforming growth
factor-b (TGF-b) as a potent regulatory cytokine with diverse
effects on T cell proliferation and differentiation [20]. In order to
better appreciate PP14’s impact on T cell activation and
differentiation we compared its effects to that of TGF-b by also
stimulating cells with MBP for 2 weeks in the presence of TGF-b
followed by restimulation with MBP, this time in the absence of
TGF-b.
Stimulation of the cells with MBP resulted in a predominant
Th1 response, with IFN-c being the main cytokine secreted with
elevating levels that correlated with increasing proliferation.
However, PBMC that were stimulated with MBP in the presence
of PP14-c during the first two weeks of stimulation showed an
impaired IFN-c response upon restimulation, at all levels of
proliferative response (Fig. 1, A and B). Interestingly, there was no
increase in Th2 or Th17 cytokine secretion (data not shown),
indicating that the inhibition of Th1 response by PP14-c is not
accompanied by a skew toward these responses. Stimulation of the
cells in the presence of TGF-b (during the first two weeks) led to
complete inhibition of IFN-c secretion upon restimulation (data
not shown).
Previous reports suggested that patients with autoimmune
diseases and specifically with multiple sclerosis (MS) have an
immune deviation with predominance of Th17 response [21].
Cytokine secretion analysis in healthy donors versus MS-derived T
cells revealed that while IFN-c secretion in both groups was
approximately the same, higher levels of IL-17 were secreted by
MS-derived T cells as can be clearly seen when data presented as
IFN-c to IL-17 ratio. Interestingly, this difference in IFN-c:IL-17
ratio was not only observed in an antigen-specific (MBP)
Figure 1. PP14?Fcc1-treated cells secrete reduced levels of IFN-c upon restimulation. PBMC from healthy donors were stimulated with
MBP (20 mg/ml) in the presence or absence of PP14?Fcc1 (50 mg/ml) for two weeks. After two weeks the cells were split and restimulated with MBP
for three days. Conditioned media of responding cells were collected, from one plate, and pooled based on the proliferation measured by H3-
thymidine incorporation in the parallel plate. Levels of secreted IFN-c in conditioned media were measured by ELISA. A, One representative
experiment out of 5 is shown. B, The average inhibition of IFN-c secretion by PP14 in 5 experiments is shown.
doi:10.1371/journal.pone.0012868.g001
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stimulation but also in polyclonal stimulation with anti-CD3 (Fig.
S1, A and B). Significantly, in both MBP and anti-CD3 stimulated
MS-derived cells, PP14?Fcc1 significantly inhibited both IFN-c
and IL-17 secretion (Fig. S1, C and D, respectively), suggesting it’s
capability to inhibit these cytokines in both normal and MS
pathological conditions despite the predominant Th17 response in
the latter.
PP14?Fcc1-treated MBP-specific T cells display an
activated phenotype
Although PP14?Fcc1 pre-treated cells exhibit impaired cytokine
secretion, several observations indicate that these cells are
activated. Despite their reduced levels of IFN-c secretion (Fig. 1),
PP14?Fcc1 pre-treated cells proliferated as much as control MBP-
activated cells upon restimulation (Fig. 2). In general, the
proliferative response of PP14?Fcc1 pre-treated cells was only
slightly decreased as compared to control MBP-activated cells, as
measured by their H3-thymidine incorporation. In contrast,
activation of cells in the presence of TGF-b during the first two
weeks resulted in complete inhibition of their proliferation upon
restimulation (Fig. 2).
To further follow the activation status of the PP14-treated cells,
T cells were immunostained for the expression of the activation
marker, CD25. Flow cytometry analysis revealed that PP14?Fcc1
pre-treatment did not significantly reduce the percentage of
CD25+ cells, compared to control MBP-stimulated cells. In
contrast, TGF-b significantly inhibited the expression of CD25
(Fig. 3). In addition, PP14?Fcc1 pre-treated cells appeared to be
activated similar to MBP-stimulated cells, as measured by
lymphocyte blast transformation (Fig. S2, B and C, respectively).
In contrast, TGF-b pre-treated cells are almost completely
inhibited and display a scatter profile that is similar to that of
non-stimulated cells (Fig. S2, D and A, respectively). Paralleling
the respective effect of PP14?Fcc1 and TGF-b on cell prolifera-
tion, these data further support the activated phenotype of
PP14?Fcc1-treated cells.
Increased numbers of CD25+FOXP3+ T cells in PP14?Fcc1
pre-treated cultures
Despite the activated phenotype of PP14?Fcc1-treated cells,
they do not seem to bear effector functions as demonstrated by
their failure to secrete cytokines of either effector T cell lineage.
This led to the hypothesis that PP14?Fcc1 treatment might
enhance a regulatory fate in the treated cells. Indeed, although the
percentage of CD25+ cells in PP14?Fcc1 pre-treated cells and
control MBP-cells was similar, the percentage of FoxP3+ cells
within these CD25+ cells was two-fold higher in PP14?Fcc1 pre-
treated cells as compared to control MBP-cells. TGF-b, the
hallmark FoxP3 inducer, induced an average of 3-fold increase in
the number of CD25+FoxP3+ cells among MBP-reactive activated
cells (Fig. 4). These results were further corroborated at the level of
mRNA using quantitative Real-Time PCR analysis with a two-
fold and four-fold increase in FoxP3 gene expression over control
MBP-activated cells, in PP14?Fcc1 and TGF-b pre-treated cells,
respectively (data not shown).
Figure 2. PP14?Fcc1-treated cells proliferate as much as control
MBP-stimulated cells upon restimulation. PBMC from healthy
donors were stimulated with MBP (20 mg/ml) in the presence or
absence of PP14?Fcc1 (50 mg/ml) or TGF-b (5 ng/ml) for two weeks.
After two weeks the cells were restimulated with MBP for three days
and cell proliferation was tested by H3-thymidine incorporation (cpm).
One representative experiment out of 5 is shown and each dot
represents cell proliferation in a single well of a 96-well plate (p#0.05).
doi:10.1371/journal.pone.0012868.g002
Figure 3. PP14?Fcc1 pre-treated cells express the activation
marker CD25. PBMC from healthy donors were stimulated with MBP
(20 mg/ml) in the presence or absence of PP14?Fcc1 (50 mg/ml) or TGF-b
(5 ng/ml) for two weeks. After two weeks the cells were restimulated
with MBP for three days and then were collected and immunostained
for the expression of CD25 on T cells (CD3+ cells).
doi:10.1371/journal.pone.0012868.g003
Figure 4. Increased numbers of CD25+FOXP3+ T cells in
PP14?Fcc1 pre-treated cultures. PBMC from healthy donors were
stimulated with MBP (20 mg/ml) in the presence or absence of
PP14?Fcc1 (50 mg/ml) or TGF-b (5 ng/ml) for two weeks. After two
weeks the cells were restimulated with MBP for three days and then
were collected and immunostained for the expression of FoxP3 by
activated CD25+ T cells.
doi:10.1371/journal.pone.0012868.g004
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PP14 induces de-novo generation of CD25+FoxP3+ cells
Since MBP-clones were generated from peripheral blood cells
that already contain native peripheral CD25+FoxP3+ cells, their
increased numbers in PP14?Fcc1-treated wells can result either
from expansion of the native Treg population or due to the
emergence of adaptive FoxP3+ T cells from naı¨ve cell population.
To test this latter possibility we activated CD4+CD252FoxP32 T
cells with various concentrations of immobilized anti-CD3 and
anti-CD28 mAb with or without PP14?Fcc1 or TGF-b, for 7 days.
As previously reported with human cells [21], anti-CD3
stimulation by-itself induced FoxP3 expression in around 5
percent of the cells. Both PP14?Fcc1 and TGF-b treatments
increased the percentage of CD25+FoxP3+ T cells above that of
anti-CD3 alone, although the effect of TGF-b was more
pronounced (Fig. 5, A and B). Furthermore, PP14?Fcc1-induced
CD25+FoxP3+ cells are characterized as CD25highand were found
to express the tumor necrosis factor (TNF)-superfamily member,
GITR (glucocorticoid-induced TNF receptor family related
protein), the typical marker of Treg [22,23] (Fig. S3, B and D).
The interplay of between PP14 and Retinoic Acid
Several recent studies have demonstrated that all-trans retinoic
acid (RA) enhances the TGF-b–dependent FoxP3 expression and
the conversion of naive T cells into Treg cells [24,25,26]. RA is of
special interest here, given that PP14 is a lipocalin that can carry
small hydrophobic ligands like retinoids in its hydrophobic pocket
[27]. In an unpublished study we have previously shown that PP14
binds to two retinoids (all-trans retinoic acid and 13-cis-retinal) in a
selective fashion, with no binding to two other retinoids (all-trans-
retinal and all-trans-retinol). We therefore examined the effect of
RA on PP14?Fcc1-induced FoxP3 expression. The addition of RA
to PP14?Fcc1-treated cultures had a minimal effect on the
percentage of PP14-induced CD25+FoxP3+ T cells while, as
expected, enhanced TGF-b-induced FoxP3 expression (Fig. 6A).
Interestingly, though RA had no effect on PP14?Fcc1-induced
FoxP3 expression, it significantly abrogated its T cell inhibitory
activity as measured by IFN-c secretion (Fig. 6B).
The addition of RA receptor-a (RARa) agonist could mimic RA
effect on PP14’s activity and the combination of RA with RARa
antagonist abrogated RA’s effect and restored PP14’s inhibitory
activity (Fig. 6C). These results suggest that RA’s observed effect
on PP14 activity is mediated through RA putative receptor and
not as a result of its binding to PP14’s hydrophobic pocket. In
aggregate, these data indicate that in contrast to TGF-b, RARa
signaling has no effect on PP14’s induction of FoxP3 expression.
Hence, we propose that PP14 and TGF-b induce FoxP3
expression via different pathways.
Inhibition of PI3K mTOR signaling pathway by PP14
TGF-b is a potent inducer of FoxP3 expression, yet it has been
suggested that in contrast to mouse, stimulation of human
CD4+CD25– T cells led to FoxP3 expression and acquisition of
Treg activity via TCR signaling, independently of TGF-b
signaling [21]. Specifically, Sauer et al have shown that that pre-
mature termination of TCR triggering, either by TCR signal
withdrawal or specifically by PI3K inhibitor significantly increased
FoxP3 expression by naı¨ve T cells, in the absence of TGF-b [28].
This finding supports the role of TCR-induced PI3K-AKT-
mTOR signaling pathway in regulating FoxP3 expression [28].
Therefore, it is possible that PP14 induces FoxP3 expression as a
consequent of its ability to modulate TCR signaling events
[13,14,29] and possibly reduce the duration of PI3K–mTOR
signaling pathway. For that end, CD4+CD25– T cells were
stimulated with immobilized-anti-CD3 mAb and anti-CD28 with
or without PP14?Fcc1 and phosphorylated S6 (pS6), a direct
ligand of the mTOR pathway, was detected at various time points
after stimulation using immunoblotting. Low levels of phosphor-
ylation were detected 15 and 30 minutes after stimulation that
were increased in the presence of PP14?Fcc1 (Fig. 7, upper panel).
At later time points, from 1 h to 18 h following stimulation, S6
phosphorylation was strongly enhanced, yet significantly inhibited
by PP14?Fcc1 at these later time points (Fig. 7, lower panel). It
seems that PP14 shortens the duration of TCR-induced mTOR
signaling, hence providing a possible mechanism for the induction
FoxP3 expression in these cells.
Discussion
Following activation, human naı¨ve CD4+ T cells can develop
into a range of T helper lineages characterized by distinct cytokine
profiles with IFN-c and IL-4 being the signature cytokines of Th1
and Th2 cells, respectively, and IL-17 for the newly identified
lineage, Th17 [30,31,32,33,34,35].
Figure 5. PP14?Fcc1 induces de-novo generation of CD25+FoxP3+ cells. Naive CD4+CD252 T cells were stimulated for one week with beads
coated with various anti-CD3 concentrations in combination with soluble anti-CD28 (0.5 mg/ml) in the presence or absence of either PP14?Fcc1
(50 mg/ml) or TGF-b (5 ng/ml). After one week the cells were collected and expression of CD25 and FoxP3 was analyzed using flow cytometry
analysis. Results are presented as fold of increase in the percentage of cells expressing FoxP3 over that induced by TCR triggering alone (dotted line,
A). One representative experiment is shown (A) and the average of seven separate experiments is shown in B (p#0.05).
doi:10.1371/journal.pone.0012868.g005
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In the present study we explored the possible impact of the
pregnancy associated immunomodulatory lipocalin, PP14, on this
CD4+ T cells developmental fate. Several previous studies
uncovered the T cell immunoregulatory properties of PP14, and
defined key aspects of its mode of action. The pivotal findings were
that PP14 targets an early stage of CD4+ T cell activation [14,29]
via a unique immunoregulatory mechanism — ‘‘rheostatic’’
desensitization of T cell receptor signaling [13]. In delving into
molecular and cellular underpinnings of this rheostatic regulatory
mechanism, it was determined that PP14 constitutes a unique class
of lipocalin/lectin immunoregulator [16] that may function via
perturbation of immune synapses and consequent interference
with summation of TCR-triggered signals [29,36].
One intriguing implication of this mode of action that was
demonstrated using polyclonal activated T cells is the preferential
inhibition by PP14 of Th1, as opposed to Th2, responses [17].
This latter observation has prompted us to suggest that PP14 may
skew the course of T helper polarization towards Th2. The focus
of early studies in our lab was on early events in T cell activation.
In going beyond the early TCR triggering process and short term
T cell responses we now attempted to understand how PP14 helps
shape the emergent T helper cell (Th) repertoire. Hence, in the
present study we focused on long-term assays of MBP-specific T
cells, in order to address how PP14 may impact T helper subset
polarization per se. For that end, we stimulated cells with MBP in
the absence or presence of PP14?Fcc1 (or TGF-b as a control) for
two weeks, a period that is sufficient for T helper polarization
[37,38]. To test their polarization fate we then re-stimulated the
cells with MBP (this time in the absence of PP14?Fcc1 or TGF-b)
and cell proliferation, activation and cytokine secretion were
analyzed. MBP stimulation led to a predominant Th1 response,
with dominant secretion of IFN-c. As expected, PP14 pre-treated
cells displayed impaired IFN-c secretion. However, in contrast to
our initial assumption that PP14?Fcc1 treatment would result in
the inhibition of Th1 response that is accompanied by a skew
towards a Th2 response, our findings unravel an unexpected
outcome. Despite the inhibition of IFN-c secretion in PP14?Fcc1 -
treated cells we found almost no secretion of IL-5, IL-4, suggesting
that inhibition of Th1 response by PP14?Fcc1 is not accompanied
by a shift towards a Th2 response. A third and newly defined
Figure 6. Retinoic acid enhances TGF-b but not PP14?Fcc1-induced FoxP3 expression, and abrogates PP14?Fcc1’s inhibitory
activity. A, Naive CD4+CD252 T cells were stimulated with beads coated with various anti-CD3 concentrations and anti-CD28 (0.5 mg/ml) for 1week
in the presence or absence of either PP14?Fcc1 (50 mg/ml) or TGF-b (5 ng/ml), with or without retinoic acid (10 nM). After one week the cells were
collected and expression of CD25 and FoxP3 was analyzed using flow cytometry. One representative experiment out of 3 is shown. B, Conditioned
media of stimulated cells was collected and analyzed for IFN-c secretion using ELISA. Data is presented as percentage of inhibition of IFN-c secretion
by PP14. An average of three independent experiments is shown. C, Cells were stimulated with anti-CD3 (0.1 mng/ml) for three days in the presence
or absence of g/ml) with or without 10 mnM of All-trans-retinoic acidm1 (50cPP14NFc agonist, a(RA). In the indicated wells, RA was replaced by the RAR
antagonist GR-110 was added in aAM-580, whereas in other wells the RAR combination with RA. After three days conditioned media were collected
and IFN-c secretion was measured using ELISA. One representative experiment of three independent experiments is shown. The data represent the
mean of triplicate samples (p#.05).
doi:10.1371/journal.pone.0012868.g006
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subset of T helper cells, that are distinct from Th1 and Th2 cells, is
the Th17 subset of cells that secrete mainly IL-17. Interestingly,
the inhibition of Th1 response by PP14 is neither accompanied by
a shift towards a Th17 response, as demonstrated by cytokine
secretion profile of the cells showing no increase of IL-17 secretion.
Th17 cells play a major role in the pathogenesis of several
autoimmune diseases, including Multiple Sclerosis (MS) and it is
assumed that there is a general immune deviation in MS patients
towards Th17 response [39]. Therefore, we tested the effect of
PP14 on T helper response in MS-derived PBMC. First, we
analyzed cytokine secretion of MS patients and healthy donors
and found that although IFN-c secretion was predominant in
both, IL-17 secretion was significantly increased in MS patients, as
can be seen when the ratio of IFN-c to IL-17 is presented.
Interestingly, this skew toward IL-17 secretion is seen when cells
were activated specifically by MBP as well as by polyclonal
activation using anti-CD3. This finding suggest that the skew is not
specific for the antigen (i.e. MBP) that is driving MS, per se, but is
a more general predisposition of these patients T cells.
Yet, despite the predisposed immune deviation of MS-derived
PBMC, stimulation of these cells in the presence of PP14?Fcc1 led
to a significant inhibition of cytokine secretion of all T helper
lineages.
We initiated this study with the expectation, based on our
previous studies, that T cell activation and proliferation would be
reduced by PP14. However, in the present study we observed an
unexpected outcome. Although cells initially stimulated with MBP
in the presence of PP14?Fcc1 displayed an impaired cytokine
secretion upon restimulation, these cells appeared to be activated
as demonstrated by their proliferative response. Activation of the
cells was also manifested by lymphocyte blast transformation, and
expression of the activation marker, CD25. In contrast, cells that
were initially stimulated in the presence of TGF-b, did not display
any of the above mentioned activation parameters and resembled
unstimulated cells.
Together, these results suggest that PP14 uncouples T cell
activation events (expression of activation markers and prolifera-
tion from cytokine secretion) that are otherwise linked. Since we
have previously demonstrated that in contrast to other T cell
inhibitors (such as cyclosporine A) PP14 functions by decreasing
the stability of TCR-induced phosphoproteins and hence
desensitisizing TCR signaling events [13], we assume that by
selectively interfering with the signal cascade initiated by TCR
triggering, PP14 eventually prevents the completion of the
differentiation and polarization into either lineages of effector T
cells and expression of the appropriate cytokines.
Several reports support the idea that various signaling pathways
regulate different T cell responses and as a consequence these
apparently linked responses can be dissociated and be regulated
separately. Dong et al. have shown that c-Jun amino-terminal
kinase (JNK)2/2 T cells produced IL-2 and proliferated, however,
production of effector T-cell cytokines did require JNK. Thus, the
authors concluded that JNK is necessary for T-cell differentiation
but not for naive T-cell activation [40]. In another study, McClain
et al., have shown that pregnant mice show a reduction in the
incidence and clinical severity of EAE. This effect was associated
with reduced levels of TNF-a as well as IL-17 expression with no
increase in Th2 responses. However, in these mice T cell
proliferation and expression of activation markers were unaffected
[41]. Interestingly, we have recently observed a similar phenom-
enon where human T cells stimulated in the presence of allogeneic
lymphocytes derived from decidual tissue expressed activation
markers and proliferated but their cytokine response was impaired
[42]. These two latter findings are specifically appealing since
PP14 is a major secretory protein of human endometrial epithelial
cells during pregnancy and its concentrations rise rapidly in early
pregnancy [3,43,44]. Our results demonstrating selective inhibi-
tion of T cell effector functions in PP14?Fcc1-treated cells may
provide a possible link between PP14 and immunoregulation by
this unique decidual lymphocyte population [42], as well as the
general changes in T cell responses during pregnancy
[45,46,47,48].
Besides Th1, Th2 and Th17 effector cells, naı¨ve CD4+ cells can
also differentiate into regulatory T cells (Treg). Regulatory T cells
expressing the transcription factor FoxP3 represent a pivotal
subset of Tregs for dominant control of adaptive immune
responses in the periphery [49,50]. This formation of distinct
lineages of effectors or regulatory T cells from naı¨ve cells in
response to Ag stimulation is a characteristic of the adaptive
immune system. The outcome of T cell responses, immunity or
tolerance is critically dependent on the balance between effectors
and regulatory T cells. Having shown that PP14 inhibits the
generation of effector T cells, we further asked whether it might
push the cells towards a regulatory fate. Our data demonstrated an
increase of up to two-fold in percentage of FoxP3-expressing cells
in the presence of PP14?Fcc1, compared to untreated cultures.
The increase in the number of FoxP3-expressing cells in the
presence of PP14?Fcc1 can be attributed to either the expansion of
already-existing peripheral Treg or, alternatively, to de-novo
generation of Treg cells from naı¨ve population. We evaluated
de-novo generation of Treg by stimulating CD4+CD252 FoxP32 T
cells in the presence of PP14?Fcc1. It has been shown that in vitro
TCR stimulation of human CD4+CD252 T cells in the absence of
TGF-b induces FoxP3 expression and conversion to Treg cells
[21]. This induction of FoxP3 by TCR stimulation is unique to
human T cells but not to mice T cells where TGF-b is
indispensable and TCR stimulation by itself is not sufficient for
FoxP3 expression [49]. In agreement with these studies, our data
suggest that TCR stimulation by itself induces FoxP3 expression
Figure 7. PP14?Fcc1 inhibits the accumulation of TCR-induced
phosphorylated ribosomal protein S6. Naive CD4+CD252 T cells
were stimulated with anti-CD3 (5 mg/ml) coated beads and anti-CD28
(0.5 mg/ml) in the presence or absence of PP14?Fcc1. Cells were
collected at the indicated time points after stimulation, lyzed and
phosphorylated S6 was analyzed using Western blot analysis. Immu-
noblotting of actin reveals relative amounts of protein in each lane
(lower panels).
doi:10.1371/journal.pone.0012868.g007
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independent of TGF-b, and as expected stimulation in the
presence of TGF-b induced a four-fold increase in the number
of FoxP3 expressing cells, compared to TCR stimulation alone.
Interestingly, PP14?Fcc1 induced a two-fold increase in the
number of FoxP3 expressing T cells that are characterized as
CD25high and GITRhigh cells. Together, these results support the
assumption that PP14 can induce de-novo generation of Treg
although not excluding the possibility that in the MBP-stimulated
cultures expansion of native Treg cells takes place, as well.
TGF-b signals by binding its cell-surface serine/threonine
kinase receptors, which in turn phosphorylate Smad2 and Smad3
that enter the nucleus and regulate FoxP3 gene expression
[26,51,52]. Retinoic acid (RA) is known to strongly enhance the
TGF-b-dependent conversion of naı¨ve T cells into FoxP3+ T cells
by increasing the expression and phosphorylation of Smad3 [26].
We asked whether it would have a similar beneficial effect on
PP14’s induction of FoxP3 expression. Surprisingly, we found that
unlike its positive effect on TGF-b signaling and FoxP3 induction,
RA had no effect on PP14?Fcc1-induced FoxP3 expression. In
contrast, RA significantly abrogated the inhibitory effect of
PP14?Fcc1 and restored cytokine secretion. Significantly, this
latter negative effect is mediated by the binding of RA to its
putative receptor and not by binding to PP14’s hydrophobic
pocket, as RA receptor agonists could replace RA, and RA
receptor antagonists abrogated this negative effect of RA on PP14
activity.
Taken together, it is most likely that TGF-b and PP14 induce
FoxP3 expression through distinct pathways that in the case of
PP14 does not involve the Smad signaling. Since, as mentioned
above, in humans, FoxP3 expression can be directly induced by
TCR stimulation even in the absence of TGF-b, it is possible that
the regulation of FoxP3 expression by PP14 is based on its ability
to modulate TCR-evoked signaling. Our earlier studies have shed
light on the way PP14 modulates T cell responses. First, we have
demonstrated that PP14 acts through the tyrosine phosphatase
receptor, CD45 [14]. Moreover, PP14 does not seem to inhibit
tyrosine kinase activity per se but rather impedes TCR signaling via
an alteration of the local balance between tyrosine kinases and
phosphatases and consequently shortening the phosphorylated
state of TCR-induced phosphoproteins.
Since commitment of T cells to cytokine production and
proliferation requires sustained TCR signaling for up to several
hours, PP14 may modulate T cell activation by reducing the
duration of TCR signaling. Sauer et al. have shown that
premature termination of TCR engagement 18 h after TCR
triggering or, alternatively, selective inhibition of the PI3K/Akt/
mTOR pathway induces FoxP3 expression and Treg-like gene
expression profiles, in a TGF-b independent way [28].
In agreement with our previous observation [29], we demon-
strated that S6 phosphorylation, an event regulated by mTOR
[53,54,55], is not simply sustained but is gradually accumulating
over time following TCR triggering. In accordance with the above
proposition for PP14 activity we show that PP14?Fcc1 inhibits S6
phosphorylation at late but not early time points. This may suggest
that the observed increase in FoxP3 expression (and most likely the
inhibition of effector functions) in PP14?Fcc1-treated cells is a
result of premature termination of TCR signaling and specifically
of the PI3K/Akt/mTOR pathway. Interestingly, our results are
strikingly supported by a recent study published by Powell et al.
[56] showing that mTOR-deficient T cells display normal
activation but fail to differentiate into Th1, Th2 and Th17
effector cells. The normal activation of the cells is attributed to the
intact AKT activation upstream to mTOR. Moreover, under
normal activating conditions, T cells lacking mTOR differentiated
into Foxp3+ regulatory T cells in the absence of exogenous TGF-
b. Specifically, it was shown that Treg differentiation in mTOR-
defficient T cells is mediated by TORC2 signaling. Normally,
TORC2 signaling is negatively regulated by TORC1, and indeed
in this study TORC1 signaling was absent, as confirmed by
impaired S6 phosphorylation.
Taken together, it appears that through regulating mTOR
signaling PP14 may have an important influence on determining
antigen-induced fate with regard to the development of effector
versus regulatory T cells. Therefore, PP14 appears to have a
potential therapeutic effect in T-cell mediated autoimmune
diseases by preventing effector T cell development and promoting
immune tolerance.
Materials and Methods
Ethics Statement
Blood samples from healthy donors were obtained from
Hadassah Medical Center Blood Bank under approval of
Hadassah Medical Center Helsinki Ethics Committee. Blood
samples of MS patients were obtained from 14 non-treated
patients (8 females, 6 males) with relapsing-remitting MS (EDSS
0.5–7) under approval of Hadassah Medical Center Helsinki
Ethics Committee following signing on informed consent. The age
range of the patients was 20–64 years with a mean age of 35 years.
Cells
Peripheral blood mononuclear cells (PBMC) were purified from
the venous blood of healthy donors or MS patients by density
gradient centrifugation using Ficoll-Hystopaque (Sigma Aldrich,
St Louis, MI, USA), as previously described [42]. The cells were
cultured in RPMI medium (Biological Industries, Beit-Haemek,
Israel) supplemented with 10% heat inactivated FCS, 2 mM
glutamine and penicillin/streptomycin (Biological Industries) at
37uC, 5% CO2 incubator. CD4+CD252 naı¨ve T cells were
purified by first isolating CD4+ T cells from the venous blood of
healthy donors using RosetteSep human CD4 T cell enrichment
mixture (StemCell Technologies, Vancouver, Canada). Next,
CD25+ cells were depleted using anti-CD25 microbeads with
magnetic cell isolation system (Miltenyi Biotec, Bergisch Glad-
bach, Germany). The resulting cell population was CD4+CD252
and FoxP32 cells as verified by flow cytometry analysis.
CD4+CD252 cells were cultured in 24-well plates (106 cells/well)
in RPMI 1640 medium (Biological Industries) supplemented with
10% heat-inactivated FCS, 2 mM glutamine, and penicillin/
streptomycin (Biological Industries) at 37uC, 5% CO2 incubator.
Production of PP14?Fcc1
Stable 293 cell (ATCC) transfectants secreting PP14?Fcc1 [14]
were grown in DMEM medium, hygromycin B (200 mg/ml;
Invitrogen), 10% heat inactivated FCS, 2 mM glutamine and
penicillin/streptomycin (Biological Industries) at 37u C with 5%
CO2. For protein purification, culture media of 293 cells secreting
PP14?Fcc1 was gradually replaced with serum-free DCCM-1
media (Biological Industries). After 48 hours of serum-free culture
the conditioned media were collected and passed through a
chromatographic column (C10/10, Amersham) prepared with
Protein-A sepharose beads (Sigma-Aldrich, St. Louis, MO), at
room temperature. Column was then washed with 20 mM
Phosphate buffer pH 7 and 100 mM citrate pH 6. PP14-Fc c1
was eluted from column with 100 mM citrate pH 3 and eluted
fraction was titrated with 1M TRIS pH 9. PP14?Fcc1 was
concentrated and buffer exchanged into 40 mM citrate pH 6
using Centricon-10 filters (Millipore, Bradford, MA).
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Generation of MBP-specific T cells
For MBP activation experiments, PBMC from healthy donors
or MS patients were plated in round bottom 96-well microplates
(26105 cells/well), in the presence of 20 mg/ml of bovine myelin
basic protein (MBP, Sigma-Aldrich) and in the absence or
presence of either PP14?Fcc1 (50 mg/ml) or TGF-b (5 ng/ml,
R&D Systems, Minneapolis, MN). After two weeks, the cultures
were split into two replicate plates that were restimulated with
irradiated autologous PBMC (350 Rads, 105 cells/well) and MBP,
for 3 days. One of the replicate plates was pulsed with H3-
thymidine (1 mCi/well, Amersham, Arlington Heights, IL) and
wells exhibiting at least 3-fold higher H3-thymidine incorporation
as compared to control wells were considered MBP-reactive wells.
Cells and media from the corresponding wells in the replicate plate
were collected either individually or as pools according to their
proliferative response, and were further analyzed by flow
cytometric analysis and ELISA, respectively.
Induction of de novo expression of FoxP3
CD4+CD252 cells were stimulated for one week with anti-CD3
mAb (OKT3; eBioscience) immobilized at the indicated concen-
trations on protein A-sepharose beads (Sigma-Aldrich) in combi-
nation with soluble anti-CD28 mAb (0.5 mg/ml; R&D Systems), in
the presence or absence of PP14?Fcc1 (50 mg/ml) or TGF-b
(5 ng/ml, R&D Systems). In the indicated experiments the
following treatments were added: 10 nM All-Trance Retinoic
acid (RA; Sigma-Aldrich), 1 mM AM-580 RA-agonist or 5 mM
GR-110 RA-antagonist (Biomol International). After one week the
cells and conditioned media were collected and analyzed by flow
cytometry and ELISA for the analysis of FoxP3 expression and
cytokine secretion, respectively.
Cytokine secretion analysis
PBMC were stimulated with MBP for two weeks and then
restimulated with MBP as described in Generation of MBP-specific T
cells. 72 hours after restimulation conditioned media were
collected and IFN-c, IL-5 and IL-17 levels were analyzed by
ELISA (R&D Systems). Conditioned media were further analyzed
using FlowCytomix human Th1/Th2 11plex KIT (Bender
MedSystems, Burlingame, CA). In experiments using
CD4+CD252, cells were stimulated for one week, as described
in Induction of de novo expression of FoxP3, and conditioned media were
analyzed for IFN-c and IL-17 secretion by ELISA (R&D Systems).
Flow cytometry
MBP-reactive cells were collected after 72 hours of restimula-
tion and CD4+CD252 were collected after one week of
stimulation and analyzed by flow-cytometry. Cell-surface markers
were detected using the following Abs in various combinations:
APC-conjugated mouse anti-human CD3 (IQ Products, Gronin-
gen, The Netherlands), FITC-conjugated mouse anti-human CD4
and PE-conjugated mouse anti-human CD25 (eBioscience). GITR
expression was detected using APC-conjugated mouse anti-human
GITR Ab (R&D Systems). FoxP3 expression was detected by
intracellular staining using anti-human FoxP3 staining set with
FITC-conjugated rat anti-human FoxP3 Ab (eBioscience), accord-
ing to the manufacturer instructions.
Western Blot
Naı¨ve CD4+CD252 cells were stimulated with immobilized
anti-CD3 mAb in combination with soluble anti-CD28 mAb, as
described in Induction of de novo expression of FoxP3, in the presence or
absence of PP14?Fcc1. Cells were collected at various time points
after stimulation and lyzed as previously described [57]. Lysates
were separated by electrophoresis on 10% SDS-PAGE gels and
then transferred to PVDF membranes (Bio-Rad, Hercules, CA).
The blots were probed with anti- phospho-Ribosomal Protein S6
antibody (R&D Systems) and HRP-conjugated goat anti-rabbit
IgG (Jackson ImmunoResearch, West Grove, PA) as a secondary
Ab. Membranes were processed with ECL Plus Western Blotting
Detection System (Amersham-Pharmacia Biotech), and exposed to
Chemiluminescence BioMax Light Film (Kodak-Industries, Ce-
dex, France). Following stripping, the membranes were re-probed
with anti-b-Actin mAb (Sigma-Aldrich) and goat anti-mouse IgG
in DakoCytomation Envision+System-HRP labeled Polymer
(DakoCytomation, Carpinteria, CA).
Statistical analysis
The student paired two-tailed t test was used. Values of p# 0.05
were considered significant.
Supporting Information
Figure S1 PBMC from MS patients exhibit increased IL-17
secretion and are inhibited by PP14NFcc1. PBMC from healthy
donors (n = 10) or MS patients (n = 3) were stimulated with MBP
for two weeks and then restimulated with MBP for three days, as
described in materials and methods (A and C). In a parallel
experiment, PBMC from healthy donors (n = 22) and MS patients
(n = 14) were stimulated with anti-CD3 (1 ng/ml) in 96-well plate
(105/well) for three days (B and D). The levels of IFN-c and IL-17
in the conditioned media were analyzed using ELISA and is
presented as the ratio between IFN-c and IL-17 in each
experiment (A and B). In one experiment PP14NFcc1 (50 mg/ml)
was added to a parallel set of MS-derived cells that were
stimulated by either MBP (C) or anti-CD3 (D) as described above,
and the levels of IFN-c and IL-17 in the conditioned media was
analyzed by ELISA. The data represent the mean of triplicate
samples.
Found at: doi:10.1371/journal.pone.0012868.s001 (0.14 MB TIF)
Figure S2 Blast transformation of PP14NFcc1 pre-treated cells
upon restimulation. PBMC from healthy donors were stimulated
with MBP (20 mg/ml) in the presence or absence of PP14NFcc1
(50 mg/ml) or TGF-b (5 ng/ml) for two weeks. After two weeks the
cells were restimulated with MBP for three days and then were
collected. The activation of the cells, as demonstrated by blast
transformation, was analyzed using flow cytometry analysis. A,
unstimulated cells, B, MBP-activated cells, C, PP14NFcc1 treated
and D, TGF-b treated T cells.
Found at: doi:10.1371/journal.pone.0012868.s002 (0.13 MB
TIF)
Figure S3 PP14NFcc1-induced FoxP3-expressing cells are
CD25high and express the Treg hallmark receptor, GITR. Naive
CD4+CD252 T cells were stimulated with anti-CD3 coated beads
and anti-CD28 (0.5 mg/ml) for one week in the presence or
absence of either TGF-b (5 ng/ml; A, C) or PP14NFcc1 (50 mg/ml;
B, D). After one week the cells were collected and the levels of
CD25 and GITR expression in FoxP3 positive (black line) and
negative cells (grey) were analyzed using flow cytometry.
Found at: doi:10.1371/journal.pone.0012868.s003 (8.73 MB TIF)
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